Cardiff Oncology Inc.

8.25+0.3700+4.70%Vol 367.73K1Y Perf 234.41%
Jun 14th, 2021 16:00 DELAYED
BID8.24 ASK8.25
Open7.93 Previous Close7.88
Pre-Market- After-Market-
 - -  - -%
Target Price
26.67 
Analyst Rating
— — 0.00
Potential %
223.27 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     59.13
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     58.83
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap309.80M 
Earnings Rating
Price Range Ratio 52W %
25.87 
Earnings Date
27th May 2021

Today's Price Range

7.938.30

52W Range

2.2325.50

5 Year PE Ratio Range

-1.50-0.6000

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
1.98%
1 Month
-3.51%
3 Months
-24.79%
6 Months
-60.03%
1 Year
234.41%
3 Years
69.75%
5 Years
-97.54%
10 Years
-88.06%

TickerPriceChg.Chg.%
CRDF8.250.37004.70
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Financial StrengthValueIndustryS&P 500US Markets
28.10
28.70
0.00
0.01
-13 426.70
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-5 573.90
-5 448.00
-6 310.40
-
RevenueValueIndustryS&P 500US Markets
370.29K
0.01
-6.83
1.71
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.14-0.140.00
Q04 2020-0.15-0.19-26.67
Q03 2020-0.20-0.195.00
Q02 2020--0.51-
Q04 2019--0.51-
Q03 2019--0.71-
Q02 2019--0.79-
Q01 2019--1.02-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.14
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume367.73K
Shares Outstanding37.55M
Trades Count3.60K
Dollar Volume13.09M
Avg. Volume1.30M
Avg. Weekly Volume332.60K
Avg. Monthly Volume505.33K
Avg. Quarterly Volume686.99K

Cardiff Oncology Inc. (NASDAQ: CRDF) stock closed at 8.25 per share at the end of the most recent trading day (a 4.7% change compared to the prior day closing price) with a volume of 370.78K shares and market capitalization of 309.80M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cardiff Oncology Inc. CEO is Mark Erlander.

The one-year performance of Cardiff Oncology Inc. stock is 234.41%, while year-to-date (YTD) performance is -54.14%. CRDF stock has a five-year performance of -97.54%. Its 52-week range is between 2.23 and 25.5, which gives CRDF stock a 52-week price range ratio of 25.87%

Cardiff Oncology Inc. currently has a PE ratio of -8.60, a price-to-book (PB) ratio of 2.37, a price-to-sale (PS) ratio of 836.66, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -33.51%, a ROC of -35.75% and a ROE of -36.18%. The company’s profit margin is -%, its EBITDA margin is -5 448.00%, and its revenue ttm is $370.29 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Cardiff Oncology Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. Cardiff Oncology Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cardiff Oncology Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Cardiff Oncology Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cardiff Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cardiff Oncology Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 25.40, ATR14 : 0.50, CCI20 : 22.32, Chaikin Money Flow : -0.18, MACD : -0.23, Money Flow Index : 59.13, ROC : 5.63, RSI : 49.21, STOCH (14,3) : 70.19, STOCH RSI : 1.00, UO : 40.85, Williams %R : -29.81), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cardiff Oncology Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

CEO: Mark Erlander

Telephone: +1 858 952-7570

Address: 11055 Flintkote Avenue, San Diego 92121, CA, US

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

40%60%

Bearish Bullish

50%50%

News

Stocktwits